



A PIONEER IN SPECIALITY PHARMACEUTICALS

HRA Pharma is a leading pharmaceutical company with a unique leadership position within niche areas of women's health and endocrinology. The company is committed to understanding evolving health needs, bringing adequate health solutions and developing actions for equal access to its products amongst patients and physicians throughout the globe.

LOCATIONS

Headquarters
Paris - France

Local presence
Belgium, France, Germany, Ireland, Italy
Luxembourg, The Netherlands,
Portugal, Spain, Switzerland, UK

STAFF

160-member multinational team

CHAIRMAN

André Ulmann

CHIEF EXECUTIVE OFFICER

Erin Gainer

2014 FINANCIAL HIGHLIGHTS

Total Revenue 70 M€
R&D investment >15%


OUR PRODUCTS

ellaOne® / ella® (ulipristal acetate)
NorLevo® (levonorgestrel)
esmya® (ulipristal acetate)
Clareva Gel™ (oxidised glycerol triester)
Lysodren® (mitotane)
Metopirone® (metyrapone)
Ketoconazole HRA™ (ketoconazole)
Mona Lisa® (copper-IUD)
Cicatridine® (hyaluronic acid)

SERVICES


LYSOSAFE® Service - European
mitotane plasma level testing network

A FAST-GROWING LEADER IN WOMEN'S HEALTH AND ENDOCRINOLOGY/RARE DISEASES




- Incorporated in 1998, HRA Pharma has a marketed portfolio of 9 pharmaceutical products, among which leading brands ellaOne®, esmya® and NorLevo®.
- Since its founding, HRA Pharma has been strongly focused on innovation, reinvesting 15% to 20% of its revenues in R&D.
- Headquartered in Paris, HRA Pharma has commercial operations in 11 EU countries and its products are sold in over 80 countries worldwide.
- The Group generated € 70m revenues in 2014 and has over 160 employees.

PORTFOLIO OF LEADING BRANDS



GROWING REVENUES AND MARGINS

Sustained double-digit growth in revenues



PARTNERING

HRA Pharma is an established and reliable pharmaceutical partner that markets both proprietary and in-licensed products via its own commercial infrastructure in Europe and its network of distribution partners around the world.

We are always interested to hear from partners who wish to manufacture, distribute our products, to help us further develop our product candidates or to license-out their products.


A FLEXIBLE MODEL BUILT ON A FOUNDATION OF R&D

A business model enabling HRA Pharma to concentrate its resources on high added-value activities of the pharmaceutical's chain, with limited capital expenditures.

An in-house strategy for innovation and R&D, development and registration of new products and the marketing of its portfolio in Europe

A solid network of partners to:

- Stimulate the search of new targets
- Outsource manufacturing of its products
- Distribute its products outside of Europe



A SOLID PRODUCT PIPELINE AND MULTIPLE EXPANSION OPPORTUNITIES

Near-term global expansion opportunities for ellaOne® and esmya®, in the US and worldwide

A strong and balanced product pipeline to drive long-term growth

- 3 clinical stage projects
- 3 pre-clinical stage projects

FOCUS ON THE ELLAONE® GLOBAL OPPORTUNITY

